PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34856074-6	2022	We demonstrate that SRC is activated in response to treatment of KRAS-mutant colorectal cell lines with MEK inhibitors (trametinib or AZD6244), and that AZD0424 abrogates this.	AZD 6244	134-141	Rous sarcoma oncogene	Mus musculus	20-23	
32876513-7	2021	The IGF2BP1-SRC/ERK2 axis is targetable by the SRC-inhibitor saracatinib and MEK-inhibitor selumetinib.	AZD 6244	91-102	Rous sarcoma oncogene	Mus musculus	12-15	
34856074-7	2022	Cell lines treated with trametinib or AZD6244 in combination with AZD0424 had reduced EGFR, FAK and SRC compensatory activation, and, cell viability was synergistically inhibited.	AZD 6244	38-45	Rous sarcoma oncogene	Mus musculus	100-103